2009 JAC In vitro activity of the ß-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
2009 ICAAC Effect of Age and Gender on the Pharmacokinetics (PK) and Safety of NXL104 in Healthy Subjects (Protocol NXL104/1004)
2009 ICAAC The Nature of Inhibition of TEM-1 ß-Lactamase by the Non-ß-Lactam Inhibitor NXL104
2009 ICAAC Activity of Ceftazidime / NXL104 and Select Comparators against Geographically Diverse Clinical Isolates of Pseudomonas aeruginosa
2009 ICAAC Pharmacokinetics (PK) and Efficacy of Ceftazidime (CAZ) / NXL104 combination in a Murine Pneumonia Model Caused by an AmpC-Producing Klebsiella pneumoniae
2009 ICAAC In Vitro Antibacterial Activity of Ceftazidime (CAZ) in Combination with the ß-Lactamase Inhibitor, NXL104
2009 ICAAC Efficacy of Ceftazidime (CAZ) /NXL104 Combination in Murine Septicaemia Caused by CTX-M-Producing Enterobacteriaceae species
2009 ICAAC Anti-Anaerobic Activity of NXL104 in Combination with ß-lactams and Metronidazole
2009 ICAAC High Resolution Crystal Structure of CTX-M-15 in Complex with the New ß-lactamase Inhibitor NXL104
2009 ICAAC In Vitro Activity of NXL104/Ceftazidime Against ß-Lactamase Producing Anaerobic Bacteria
2009 ICAAC Efficacy of NXL104 in combination with ceftazidime in murine infection models
2009 ECCMID Use of the Hollow Fibre Infection Model in the Pharmacodynamic evaluation of the Beta-lactamase Inhibitor NXL104
2008 Superbugs Ceftazidime / NXL104, an alternative to the use of carbapenems in the treatment of Gram-negative infections
2008 RICAI Activité in vitro de NXL104 sur CTX-M-15 et KPC-2 : un nouvel inhibiteur de ß-lactamases à spectre étendu (BLSE) et de carbapénèmases de classe A
2008 JAntimicChemother NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum ß-lactamases and carbapenemases
2008 ICAAC Use of NXL104, a ß-lactamase Inhibitor, to Detect Klebsiella pneumoniae Carbapenemase (KPC) in Enterobacteriaceae
2008 ICAAC Importance of NXL104 Pharmacokinetics (PK) in the Pharmacodynamics (PD) of Ceftazidime+NXL104 Combinations in an in vitro Hollow Fiber Infection Model
2008 10th BLA Meeting
 In vitro activity of the ceftazidime / NXL104 combination against Pseudomonas aeruginosa clinical isolates
2007 ICAAC Activity of the New ß-Lactamase Inhibitor NXL104 against KPC ß-Lactamases
2007 ICAAC In vitro Activity of the New ß-lactamase Inhibitor NXL104 : Restoration of Ceftazidime (CAZ) Efficacy Against Carbapenem-Resistant Enterobacteriaceae Strains
2007 ICAAC Safety, Single Dose Pharmacokinetics, and Pharmacodynamics of ß-Lactmase Inhibitor NXL104 in Healthy Young Male Adults
2007 ICAAC NXL104 / Cephalosporin Combinations vs. Enterobacteriaceae with CTX-M ESBLs
2007 ICAAC Pharmacokinetics of the New ß-Lactamase Inhibitor NXL104 in an Experimental Rabbit Meningitis Model; Restoration of the
Bacteriological Efficacy of Ceftazidime (CAZ) against a Class C Producing K. pneumoniae
2007 ECCMID The Efficacy of Ceftazidime combined with NXL104, a novel ß-lactamase inhibitor, in a mouse model of
kidney infections induced by ß-lactamase producing Enterobacteriaceae
2007 CHI NXL104 ß-lactamase inhibitor
2006 RICAI Activité in vitro de NXL104 sur SHV-4: un nouvel inhibiteur des ß-lactamases à spectre étendu
2006 RICAI Etude de l'expression d'AmpC dans Enterobacter cloacae : absence de risque d'induction avec l'nhibiteur de ß-lactamases NXL104
2006 ICAAC What's in the Pipeline?
2006 ICAAC The ß-lactamase Inhibitor NXL104 Does Not Induce ampC ß-lactamase Expression in Enterobacter cloacae:
Evaluation of ampC Expression by Quantitative Polymerase Chain Reaction (Q-PCR).
2006 ICAAC NXL104, a Novel ß-lactamase Inhibitor, Restores the Bactericidal Activity of Ceftazidime Against ESBL and AmpC Producing Strains of Enterobacteriaceae
2005 ICAAC Safety and Toxicokinetics of NXL104, a Broad Spectrum ß-lactamase Inhibitor, in the Rat
2005 ICAAC Efficacy of NXL104, a Novel Broad Spectrum ß-lactamase Inhibitor, in Combination with Ceftazidime in Murine Septicaemia and Pneumonia
2005 ICAAC In vitro activity of NXL104 (formerly AVE1330A), a New ß-lactamase Inhibitor, in Combination with Cefpodoxime and Cefixime against 3rd Generation Cephalosporin-Resistant Isolates of species of the Enterobacteriaceae
2005 ECCMID In vitro activity of AVE1330A, a novel ß-lactamase inhibitor, in combination with aztreonam or ceftazidime against ceftazidime-resistant isolates of species of the Enterobacteriaceae
2005 9th BLA MEETING Clinical potential of the ß-lactamase inhibitor NXL104 (formerly AVE1330)
2004 JAntimicChemother In vitro activity of AVE1330A, an innovative broad-spectrum non-ß-lactam ß-lactamase inhibitor
This compilation was produced by Novexel SA, Romainville, France.